DEBIO 1347 In Patients With GastroIntestinal Cancers Harboring An FGFR Gene Fusion: Preliminary Results

Presented at ESMO GI 2019, Barcelona, Spain

Ignacio Matos1, Lipika Goyal2, James M. Cleary3, Martin H. Voss4, Do-Youn Oh5, Funda Meric-Bernstam6, Matthew CH Ng7, Gopa Iyer4, Nobuya Ishii8, Youyou Hu9, Anne Vaslin9, Anna Pokorska-Bocci9, Valerie Nicolas9, Yulia Kirpicheva9, Claudio Zanna9, Keith Flaherty2, Josep Tabernero1, David Hyman4

  1. Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;
  2. Massachusetts General Hospital Cancer Center, Boston, MA;
  3. Dana-Farber Cancer Institute, Boston, MA;
  4. Memorial Sloan-Kettering Cancer Center, New York, NY;
  5. Seoul National University Hospital, Seoul, Korea;
  6. The University of Texas MD Anderson Cancer Center, Houston, TX;
  7. National Cancer Centre Singapore, Singapore;
  8. Chugai Pharmaceutical Co., Ltd., Tokyo, Japan;
  9. Debiopharm International SA, Lausanne, Switzerland